Steven Dow

Professor, Small Animal Internal Medicine; Director, Center for Immune and Regenerative Medicine Clinical Sciences

About Steven

Dr. Dow received his DVM from the University of Georgia and completed a residency in small animal internal medicine at Colorado State University. He then completed a PhD program in Comparative Pathology in the laboratory of Ed Hoover at Colorado State University. After that, Dr. Dow completed a post-doctoral fellowship at the National Jewish Center in the laboratory of Dr. Terry Potter, before joining the faculty of the Department of Clinical Sciences at CSU in 2002. He is currently a professor of immunology in the DCS and the director of the Center for Immune and Regenerative Medicine at CSU.


PhD, Colorado State University, 1992DVM, University of Georgia, 1982MS, Colorado State University, 1987BA, University of Virginia, 1978


Diplomate, Small Animal Internal Medicine
American College of Veterinary Internal Medicine


Mitchell L, Hendersen A, and Dow S. (2012) Vaccine suppression by inflammatory monocytes. J Immunology 189:5612. Elmslie R, Glawe P, and Dow S. (2008) Metronomic chemotherapy with cytoxan and piroxicam effectively delays tumor recurrence in dogs with incompletely resected soft tissue sarcoma, J Vet Intern Med, 22:1373-1379. Guth A, Hafeman S, and Dow S. (2012) Depletion of myeloid cells triggers spontaneous T cell immunity against cancer. Oncoimmunology 1:1248Webb T, Quimby J, and Dow S. (2012) In vitro comparison of feline bone marrow derived and adipose tissue derived mesenchymal stem cells. J Fel Med Surg 14:165-169.Sottnik JL, Rao S, Lafferty MH, Thamm DH, Morley PS, Withrow SJ, Dow SW. (2010). Association of blood monocyte and lymphocyte count and disease-free interval in dogs with osteosarcoma. J Vet Intern Med. 24: 1439-1444.Sottnik J, Guth A, Thamm D, and Dow S. (2010) Chronic bacterial infection suppresses tumor growth via NK cell and macrophage mediated immunity. Cancer Immunol Immunother 59:367-378.Burton J, Mitchell L, Biller B, and Dow S. (2011) Low-dose cyclophosphamide selectively decreases regulatory T cells and inhibits angiogenesis in dogs with osteosarcoma. J Vet Intern Med 25:920-925.O’Neill K, Guth A, Biller B, and Dow S. (2008) Regulatory T cells responses and tumor associations in dogs with cancer. J Vet Intern Med. Quimby JM, Webb TL, Gibbons DS, Dow SW. (2011) Evaluation of intrarenal mesenchymal stem cell injection for treatment of chronic kidney disease in cats: a pilot study. J Feline Med Surg;13:418-26.Quimby J, Webb T, Habenicht L, and Dow S. (2013) Safety and efficacy of intravenous infusion of allogeneic cryopreserved mesenchymal stem cells for treatment of chronic kidney disease in cats: Results of 3 preliminary studies. Stem Cell Res Ther 4:48.Mitchell LA, Hansen RJ, Beaupre AJ, Gustafson DL, Dow SW. (2013) Optimized dosing of a CCR2 antagonist for amplification of vaccine immunity. International Immunopharmacology15:357.Mitchell L, Dow S, Slansky J, and Biller B. (2012) Induction of remission results in spontaneous enhancement of anti-tumor cytotoxic T cell activity in dogs with lymphoma. Vet Immunol Immunopath 145:597-605.Hafeman S, Varland D, and Dow S. (2012) Bisphosphonates significantly increase the activity of doxorubicin or vincristine against canine histiocytosis cells. Vet Comp Oncol 10:44-60.Habenicht LM, Webb TL, Clauss LA, Dow SW, Quimby JM. (2012) Urinary cytokine levels in apparently healthy cats and cats with chronic kidney disease. J Feline Med Surg.Guth A, Elmslie R, Hafeman S, and Dow S. (2013) Liposomal clodronate for tumor macrophage depletion in dogs with soft tissue sarcoma. Vet Comp OncolPropst K, Troyer R, Kellihan L, Schweizer H, and Dow S. (2010) Immunotherapy markedly potentiates the effectiveness of antimicrobial therapy for treatment of Burkholderia pseudomallei infection. Antimicrob Agents Chemoth 54:1785.Norris MH, Propst KL, Yang Y, Dow S, Hoang TT. (2011) The Burkholderia pseudomallei delta asd mutant demonstrates reduced intracellular infectivity and protects against meliodosis in mouse model. Infection Immunity 79:4010-4020.Michel B, Meyerett-Reid C, Johnson T, Ferguson A, Wyckoff C, Pulford B, Bender H, Avery A, Telling G, Dow S, Zabel MD. (2012) Incunabular immunological events in prion trafficking. Sci Rep. 2012;2:440.Henderson A, Propst K, Kedl R, and Dow S. (2011) Mucosal vaccination with liposome-nucleic acid adjuvant generates effective humoral and cellular immunity. Vaccine 29:5304-5310.Goodyear A, Troyer R, Bielefeldt-Ohmann, and Dow S. (2012) MyD88-dependent recruitment of monocytes and dendritic cells required for protection in mouse model of Burkholderia mallei pneumonia. Infection Immunity 80:110-120.Kvitko BH, Goodyear A, Propst KL, Dow SW, Schweizer HP. (2012) Burkholderia pseudomallei known siderophores and hemin uptake are dispensable for lethal murine melioidosis. PLoS Negl Trop Dis. Bragg R, Duffy A, Greene A, Vier J, and Dow S. (2012) Clinical evaluation of single dose hyperimmune plasma for canine parvoviral gastroenteritis. J Am Vet Med Assoc 240:700-708.Sutherland MD, Goodyear AW, Troyer RM, Chandler JC, Dow SW, Belisle JT. (2012) Post-exposure immunization against Francisella tularensis membrane proteins augments protective efficacy of gentamicin in a mouse model of pneumonic tularemia. Vaccine. 30:4977-82.Goodyear A, Bielefeldt-Ohmann H, Schweizer H, and Dow S. (2012) Persistent gastric colonization with Burkholderia pseudomallei and dissemination from the gastrointestinal tract following mucosal inoculation in mice. PLoS One.Silva E and Dow S. (2013) Recent developments in Burkholderia vaccines. Frontiers in Medicine.Perry JA, Thamm DH, Eickhoff J, Avery AC, Dow SW. (2011) Increased monocyte chemotactic protein-1 concentration and monocyte count independently associate with a poor prognosis in dogs with lymphoma. Vet Comp Oncol 9:55-64.Skyberg J, Rollins M, Holderness J, Marlenee N, Dow S, and Pascual DW. (2012) Nasal acai polysaccharides potentiate innate immunity to protect against pneumonic Francisella tularensis and Burkholderia pseudomallei infection. PLoS Pathog

Research Specialty

Dr. Dow's research interests involve the discovery and development of new immunotherapies and vaccines for cancer and bacterial infections, and in the use of stem cell therapy for immune modulation. Clinical interest: Cancer immunotherapy and immune modulation for common cancers of dogs and catsClinincal interest: Clinical Immunology (autoimmune diseases, immune deficiency disorders) Clinical interest: stem cell therapy for immune modulation and antimicrobial activity in dogs and catsClinical interest: Infectious diseases, including chronic bacterial and fungal infections